May 5, 2010 (Toronto) - Mylan Pharmaceuticals ULC today announces it has launched Mylan-Nifedipine Extended Release tablets in 30 mg strength. Mylan is the only company in Canada to offer this generic alternative to Adalat® XL®. Previously available in 60 mg tablets, the addition of the 30 mg is another example of how generic manufacturers offer patients greater access to high quality products. Mylan-Nifedipine Extended Release is an important antihypertensive for patients suffering from angina and/or hypertension.

Health Canada has declared Mylan-Nifedipine Extended Release tablets bioequivalent to Adalat® XL®. "We take pride in being the first and only company to offer a generic alternative to Adalat® XL® in Canada," said Dick Guest, President and CEO of Mylan in Canada. "The launch of this unique and difficult to manufacture tablet demonstrates our dedication to providing quality, more affordable medicines to the Canadian market."

Total sales for Adalat XL 30mg in Canada were approximately $81 million ($CDN) for the 12 months ending Dec. 31, 2009.

The new medicine continues a long line of Mylan products carefully made to treat angina and/or hypertension including Mylan-Amlodipine, Mylan-Ramipril and Mylan-Lisinopril.

For more information, please visit www.mylan.ca/nifedipine.

Mylan Pharmaceuticals ULC is the Canadian subsidiary of U.S.-based Mylan Inc. (Mylan), which ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. Mylan maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

Information:
Kathleen Stelmach
Torchia Communications
416-341-9929, ext. 227
kathleen@torchiacom.com